Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Other Accumulated Expenses (2016 - 2018)

Historic Other Accumulated Expenses for Vanda Pharmaceuticals (VNDA) over the last 10 years, with Q1 2018 value amounting to $2.0 million.

  • Vanda Pharmaceuticals' Other Accumulated Expenses rose 893.43% to $2.0 million in Q1 2018 from the same period last year, while for Mar 2018 it was $2.0 million, marking a year-over-year increase of 893.43%. This contributed to the annual value of $2.0 million for FY2017, which is 7583.77% up from last year.
  • Latest data reveals that Vanda Pharmaceuticals reported Other Accumulated Expenses of $2.0 million as of Q1 2018, which was up 893.43% from $2.0 million recorded in Q4 2017.
  • In the past 5 years, Vanda Pharmaceuticals' Other Accumulated Expenses ranged from a high of $2.0 million in Q1 2018 and a low of $614000.0 during Q1 2014
  • In the last 5 years, Vanda Pharmaceuticals' Other Accumulated Expenses had a median value of $1.6 million in 2015 and averaged $1.5 million.
  • Per our database at Business Quant, Vanda Pharmaceuticals' Other Accumulated Expenses soared by 455555.56% in 2014 and then plummeted by 3266.03% in 2016.
  • Over the past 5 years, Vanda Pharmaceuticals' Other Accumulated Expenses (Quarter) stood at $2.0 million in 2014, then dropped by 16.63% to $1.7 million in 2015, then plummeted by 32.66% to $1.1 million in 2016, then soared by 75.84% to $2.0 million in 2017, then rose by 1.5% to $2.0 million in 2018.
  • Its last three reported values are $2.0 million in Q1 2018, $2.0 million for Q4 2017, and $1.9 million during Q3 2017.